干扰素α-1b联合利巴韦林治疗慢性丙型肝炎64例

目的　观察干扰素α - 1b(IFNα - 1b)与利巴韦林 (ribavirin)联合治疗慢性丙型肝炎 (CHC)的疗效及安全性。方法　 6 4例CHC随机分为联合治疗组 (IFNα - 1b 加利巴韦林 ,30例 )与对照组 (单用IFNα - 1b,34例 ) ,观察两组治疗前后的疗效和毒副作用。结果　联合治疗组临床症状体征的缓解率为 93.33% ,病毒应答率为 6 3.33% ;对照组分别为 85 .30 %、47.0 6 % ,两组无显著差异 (P >0 .0 5 )。随访 6个月联合治疗组的持续应答率为 40 .0 0 % ,对照组为 14.71% ,有显著差异 (P <0 .0 5 )。联合治疗组副作用除贫血较对照组明显外 ,其他与对照组相仿。结论　干扰素联合利巴韦林治疗CHC较单用干扰素远期疗效显著且耐受性好

Treatment of chronic hepatitis C by combined interferon α-1b with ribavirin

Objective To study the efficiency and safety of interferon alpha-1b and ribavirin in the treatment of chronic hepatitis C(CHC). Methods Sixty four CHC patients were randomly divided into two groups.The combined treatment group in 30 patients received INFα-1b plus ribavirin for 6 months, 34 patients in the control group received interferonα-1b alone.The efficiency and the adverse events were evaluated. Result End-of-treatment responses achieved in the combined treatment group and the control group were 63.33% and 47.06%, respectively. Sustained response rate was greater in the combined treatment group than that in the control group (40.00% νs 14.71%, P<0.05). Except for anemia,the side effects in combined treatment group were similar than that in the control group.Conclusion The effects of combined treatment with interferon α-1 b and ribavirin significantly superior to interferon α-1b alone and the patients possess better tolerance.